Intralipid infusion at time of embryo transfer in women with history of recurrent implantation failure: A systematic review and meta‐analysis. Issue 6 (23rd March 2021)

• Record Type: Journal Article
• Authors: Rimmer, Michael P.; Black, Naomi; Keay, Stephen; Quenby, Siobhan; Al Wattar, Bassel H.
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 47:Issue 6(2021)
• Page Start: 2149
• Page End: 2156
• Publication Date: 2021-03-23
• Subjects: assisted reproductive technology -- immunotherapy -- intralipid -- recurrent implantation failure -- recurrent pregnancy loss; Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.14763
• Languages: English
• ISSNs: 1341-8076

Abstract

Abstract: Aim: Recurrent implantation failure (RIF) affects 10% of couples undergoing assisted conception, often due to poor endometrial receptivity. We conducted a systematic review and meta‐analysis to evaluate the effectiveness of Intra‐venous intralipid (IVI) in improving pregnancy rates in women with history of RIF using. Methods: We searched MEDLINE, EMBASE, and CENTRAL for any randomized trials evaluating the use of IVI at the time of embryo transfer in women undergoing assisted conception until September 2020. We extracted data in duplicate and assessed risk of bias using the Cochrane Risk of Bias tools. We meta‐analyzed data using a random effect model. Results: We included five randomized trials reporting on 843 women with an overall moderate risk of bias. All trials used 20% IVI solution at the time of embryo transfer compared to normal saline infusion or no intervention (routine care). The IVI group had a higher chance of clinical pregnancy (172 vs 119, risk ratio [RR] 1.55, 95% confidence interval [CI] 1.16–2.07, I 2 44.2%) and live birth (132 vs 73, RR 1.83, 95% CI 1.42–2.35, I 2 0%) post treatment compared to no intervention. Our findings are limited by the small sample size and the variations in treatment protocols and population characteristics. Conclusion: There is limited evidence to support the use of IVI at the time of embryo transfer in women with the history of RIF. More research is needed before adopting it in clinical practice.